Niagen Bioscience (NASDAQ:NAGE) Downgraded by Wall Street Zen to Buy

Wall Street Zen downgraded shares of Niagen Bioscience (NASDAQ:NAGE) from a strong-buy rating to a buy rating in a report published on Friday morning.

Several other equities research analysts also recently weighed in on NAGE. Canaccord Genuity Group began coverage on shares of Niagen Bioscience in a research note on Tuesday, May 27th. They set a “buy” rating and a $13.00 target price on the stock. Roth Capital upped their target price on shares of Niagen Bioscience from $10.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday.

Niagen Bioscience Stock Up 12.5%

Niagen Bioscience stock opened at $12.95 on Friday. The company has a 50 day moving average of $8.56. The stock has a market cap of $1.02 billion, a P/E ratio of 76.18 and a beta of 1.94. Niagen Bioscience has a 1 year low of $2.31 and a 1 year high of $13.12.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.